Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
The Times and Democrat18 hrs ago
149
NBC Southern California
CBS News
CBS Colorado Politics
People Human Interest
Cover Media
Reuters US Top
NBC 6 South Florida
Raw Story
The List